Abstract:The majority of current cancer immunotherapy strategies target and potentiate antitumor adaptive immune responses. Unfortunately, the efficacy of these treatments has been limited to a fraction of patients within a subset of tumor types, with an aggregate response rate of approximately 20% to date across all malignancies. The success of therapeutic inhibition of programmed death protein 1 (PD-1), protein death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with immune checkpoint inhibitors (ICI) has been limited to “hot” tumors characterized by preexisting T cell infiltration, whereas “cold” tumors, which lack T cell infiltration, have not achieved durable benefit. There are several mechanisms by which “cold” tumors fail to generate spontaneous immune infiltration, which converge upon the generation of an immunosuppressive tumor microenvironment (TME). The role of the innate immune system in tumor immunosurveillance and generation of antitumor immune responses has been long recognized. In recent years, novel strategies to target innate immunity in cancer therapy have emerged, including therapeutic stimulation of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs); the DNA sensing cGAS/STING pathway; nucleotide-binding oligomerization domain-like receptors (NLRs), such as NLRP3; and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs). In addition, therapeutic modulation of key innate immune cell types, such as macrophages and natural killer cells, has been investigated. Herein, we review therapeutic approaches to activate innate immunity within the TME to enhance antitumor immune responses, with the goal of disease eradication in “cold” tumors. In addition, we discuss rational immune-oncology combination strategies that activate both innate and adaptive immunity, with the potential to enhance the efficacy of current immunotherapeutic approaches.

Immune cells as anti-cancer therapeutic targets and tools.

Innate Immunity and Cancer Pathophysiology.

From Inflammation to Cancer: the Molecular Basis

Targeting Innate Immunity in Cancer Therapy

Chronic inflammation, cancer development and immunotherapy

Immunity, Inflammation, and Cancer

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Exploiting innate immunity for cancer immunotherapy

Roles of the immune system in cancer: from tumor initiation to metastatic progression

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

Inflammation and cancer: advances and new agents

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Cancer immunity by tissue‐resident type 1 innate lymphoid cells and killer innate‐like T cells

Cancer immunology for the clinician

Cancer and Innate Immune System Interactions

Innate Immunity in Cancer Biology and Therapy

Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment

Harnessing innate immune pathways for therapeutic advancement in cancer

Inflammation and tumor progression: signaling pathways and targeted intervention